GlassScriptPhysician profile
Kerry A Young
NPI 1144381690
$4,324.44
in general payments reported to CMS, 2019-2025
20 companies · $788 in 2025
The $788 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $40.41 · 2021: $375 · 2022: $656 · 2023: $1,015 · 2024: $860 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $10.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.02 |
| Education | $10.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,107.12 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Allergan, INC. | $650.88 | 2019-2022 | |
| Alcon Vision LLC | $607.54 | 2022-2025 | Rocklatan, Tryptyr, Rhopressa |
| Sun Pharmaceutical Industries INC. | $544.91 | 2021-2025 | Cequa, Xelpros |
| Mallinckrodt Hospital Products INC. | $245.57 | 2023 | Acthar |
| Biotissue Holdings INC. | $209.69 | 2019-2024 | |
| Tarsus Pharmaceuticals, INC. | $135.24 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $121.81 | 2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $106.96 | 2025 | |
| Shire North American Group INC | $104.60 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.38 | 2021 | |
| Dompe US, INC. | $92.78 | 2021 | |
| Thea Pharma INC. | $79.03 | 2022-2024 | Iyuzeh |
| Sight Sciences, INC. | $76.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $34.26 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $30.42 | 2023 | Tecnis Iol |
| Abbvie INC. | $25.11 | 2024 | |
| Kala Pharmaceuticals, INC. | $23.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.77 | 2023 | |
| Spark Therapeutics, INC. | $16.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.